In prostate cancer patients, tandem therapy with [177Lu]Lu-PSMA combined with low-activity [225Ac]Ac-PSMA showed promising results (Khreish et al. 2020; Rosar et al. 2021; Satapathy et al. 2021; Kratochwil et al. 2020b; Privé et al. 2022a). The gene discussed is FOLH1; the disease is prostate carcinoma.